Exact Sciences Corporation $EXAS Shares Purchased by Mairs & Power Inc.

Mairs & Power Inc. increased its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 25.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 93,237 shares of the medical research company’s stock after acquiring an additional 18,762 shares during the quarter. Mairs & Power Inc.’s holdings in Exact Sciences were worth $5,101,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EXAS. Ameriprise Financial Inc. increased its stake in Exact Sciences by 105.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company’s stock valued at $245,802,000 after purchasing an additional 2,310,139 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Exact Sciences by 31.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company’s stock worth $213,889,000 after buying an additional 939,888 shares during the last quarter. Holocene Advisors LP boosted its position in shares of Exact Sciences by 27.0% in the 3rd quarter. Holocene Advisors LP now owns 2,725,390 shares of the medical research company’s stock worth $149,106,000 after buying an additional 580,209 shares in the last quarter. William Blair Investment Management LLC grew its stake in Exact Sciences by 26.5% in the 3rd quarter. William Blair Investment Management LLC now owns 2,555,051 shares of the medical research company’s stock valued at $139,787,000 after acquiring an additional 534,881 shares during the last quarter. Finally, Champlain Investment Partners LLC increased its holdings in Exact Sciences by 12.6% during the 2nd quarter. Champlain Investment Partners LLC now owns 2,529,820 shares of the medical research company’s stock valued at $134,435,000 after acquiring an additional 282,825 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Up 0.3%

EXAS stock opened at $103.85 on Tuesday. The company has a 50 day moving average price of $102.87 and a two-hundred day moving average price of $84.53. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. The stock has a market capitalization of $19.82 billion, a P/E ratio of -94.41, a PEG ratio of 2.36 and a beta of 1.41. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $103.92.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same period in the previous year, the business posted ($0.06) EPS. The company’s quarterly revenue was up 23.1% compared to the same quarter last year. As a group, sell-side analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current year.

Analyst Upgrades and Downgrades

EXAS has been the topic of several recent research reports. Piper Sandler downgraded shares of Exact Sciences from an “overweight” rating to a “hold” rating and set a $105.00 price target on the stock. in a report on Monday, November 24th. Jefferies Financial Group downgraded Exact Sciences from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $90.00 to $105.00 in a research report on Monday, November 24th. Evercore set a $105.00 target price on Exact Sciences and gave the company an “in-line” rating in a report on Monday, January 5th. Craig Hallum downgraded Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price target for the company. in a research report on Friday, November 21st. Finally, BTIG Research cut Exact Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 20th. Twenty-one investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $92.13.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.